18f-pbr06
Small moleculeexperimentalImaging agent
Clinical trial activity
9 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT01028209)
Timeline
Indications
Studied for
- Alzheimer Disease · Phase 1/Phase 2
- Amyotrophic Lateral Sclerosis · Phase 1
- Atrophy · Phase 1/Phase 2
- Cerebellar Diseases · Early Phase 1
- Healthy Volunteers · Phase 1
- Hypotension · Early Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Multiple Sclerosis · Phase 1/Phase 2
- Multiple System Atrophy · Early Phase 1
- Parkinson Disease · Phase 1
- Stroke · Phase 2
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- (18f)n-fluoroacetyl-n-(2,5-dimethoxybenzyl)-2-phenoxyaniline
- 18f pbr06
- 18f pbr06
- 18f-pbr06
- 18f-pbr06
- 18f-pbr06
- n-fluoroacetyl-2meobzphoa
- n-fluoroacetyl-n-(2,5-dimethoxybenzyl)-2-phenoxyaniline
- pbr06
- pbr06
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04616456 | Early Phase 1 (Phase 1) | Dec 31, 2020 | Biohaven Pharmaceuticals Inc., Harvard University |
| NCT04510220 | Phase 3 | Aug 31, 2020 | Harvard University, Novartis |
| NCT04144257 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Department of Defense, Harvard University |
| NCT03983252 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2019 | Genzyme, Harvard University |
| NCT03033680 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2017 | Harvard University |
| NCT03876002 | Phase 1 | Jun 28, 2016 | Molecular NeuroImaging |
| NCT02649985 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2016 | Harvard University |
| NCT02513589 | Phase 2 | Sep 1, 2015 | University of Bordeaux |
| NCT01028209 | Phase 1 | Nov 1, 2009 | Institute for Neurodegenerative Disorders |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 6 | 6 | 3 | 2016 |
| Biohaven Pharmaceuticals Inc. | For profit | 1 | 0 | 1 | 2020 |
| Department of Defense | Government | 1 | 0 | 1 | 2019 |
| Genzyme | For profit | 1 | 0 | 1 | 2019 |
| Institute for Neurodegenerative Disorders | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Molecular NeuroImaging | For profit | 1 | 1 | 1 | 2016 |
| Novartis | For profit | 1 | 0 | 1 | 2020 |
| University of Bordeaux | Academic/Hospital | 1 | 1 | 1 | 2015 |
8 organizations
Page 1 / 1